journal article·2020-04-22

Reduction/Oxidation-Responsive Hierarchical Nanoparticles with Self-Driven Degradability for Enhanced Tumor Penetration and Precise Chemotherapy

Shaoping Yin, Yi Gao, Yu Zhang, Jianan Xu, Jianping Zhu, Fang Zhou, Xiaochen Gu, Guangji Wang, Juan Li

ACS Applied Materials & Interfaces· Volume 12· Issue 16
Publisher page

Abstract

Deep tumor penetration, long blood circulation, rapid drug release, and sufficient stability are the most concerning dilemmas of nano-drug-delivery systems for efficient chemotherapy. Herein, we develop reduction/oxidation-responsive hierarchical nanoparticles co-encapsulating paclitaxel (PTX) and pH-stimulated hyaluronidase (pSH) to surmount the sequential biological barriers for precise cancer therapy. Poly(ethylene glycol) diamine (PEG-dia) is applied to collaboratively cross-link the shell of nanoparticles self-assembled by a hyaluronic acid–stearic acid conjugate linked via a disulfide bond (HA–SS–SA, HSS) to fabricate the hierarchical nanoparticles (PHSS). The PTX and pSH coloaded hierarchical nanoparticles (PTX/pSH-PHSS) enhance the stability in normal physiological conditions and accelerate drug release at tumorous pH, and highly reductive or oxidative environments. Functionalized with PEG and HA, the hierarchical nanoparticles preferentially prolong the circulation time, accumulate at the tumor site, and enter MDA-MB-231 cells via CD44-mediated endocytosis. Within the acidic tumor micro-environment, pSH would be partially reactivated to decompose the dense tumor extracellular matrix for deep tumor penetration. Interestingly, PTX/pSH-PHSS could be degraded apace by the completely activated pSH within endo/lysosomes and the intracellular redox micro-environment to facilitate drug release to produce the highest tumor inhibition (93.71%) in breast cancer models.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, PR China

Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 210009, PR China

Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba R3E 0T5, Canada

Funding

Ministry of Education of the People's Republic of China · Ministry of Science and Technology of the People's Republic of China · China Postdoctoral Science Foundation · Government of Jiangsu Province · National Natural Science Foundation of China · Huahai Pharmaceutical Postgraduate Innovation Fund

References (53)

Show source-provided references
1. 10.1021/acsnano.8b0589310.1021/acsnano.8b05893 ↗
2. 10.1021/acsami.9b1395710.1021/acsami.9b13957 ↗
3. 10.1021/acsnano.7b0805110.1021/acsnano.7b08051 ↗
4. 10.7150/thno.2943110.7150/thno.29431 ↗
5. 10.1002/advs.20180101210.1002/advs.201801012 ↗
6. 10.1016/j.nantod.2018.06.00810.1016/j.nantod.2018.06.008 ↗
7. 10.1002/adma.20170755710.1002/adma.201707557 ↗
8. 10.1016/j.biomaterials.2018.04.03910.1016/j.biomaterials.2018.04.039 ↗
9. 10.1002/adfm.20170737110.1002/adfm.201707371 ↗
10. 10.1002/adfm.20190244010.1002/adfm.201902440 ↗
11. 10.1016/j.biomaterials.2017.12.01810.1016/j.biomaterials.2017.12.018 ↗
12. 10.1016/j.jconrel.2019.04.00310.1016/j.jconrel.2019.04.003 ↗
13. 10.1016/j.biomaterials.2017.10.02410.1016/j.biomaterials.2017.10.024 ↗
14. 10.1016/j.jconrel.2019.01.00910.1016/j.jconrel.2019.01.009 ↗
15. 10.1021/ja306616n10.1021/ja306616n ↗
16. 10.1007/s12274-018-2012-110.1007/s12274-018-2012-1 ↗
17. 10.1002/advs.20170064810.1002/advs.201700648 ↗
18. 10.1016/j.addr.2018.10.01210.1016/j.addr.2018.10.012 ↗
19. 10.1016/j.actbio.2015.08.02910.1016/j.actbio.2015.08.029 ↗
20. 10.1016/j.ijpharm.2018.08.01910.1016/j.ijpharm.2018.08.019 ↗
21. 10.1021/ar400033910.1021/ar4000339 ↗
22. 10.1039/c5cs00798d10.1039/c5cs00798d ↗
23. 10.1021/acs.nanolett.8b0073710.1021/acs.nanolett.8b00737 ↗
24. 10.1021/jacs.8b0164110.1021/jacs.8b01641 ↗
25. 10.1021/acs.nanolett.6b0163210.1021/acs.nanolett.6b01632 ↗
26. 10.1016/j.biomaterials.2014.10.07310.1016/j.biomaterials.2014.10.073 ↗
27. 10.1038/s41427-018-0068-810.1038/s41427-018-0068-8 ↗
28. 10.1021/acsami.9b0252910.1021/acsami.9b02529 ↗
29. 10.1021/acsami.8b0934210.1021/acsami.8b09342 ↗
30. 10.1002/anie.20171162910.1002/anie.201711629 ↗
31. 10.1016/j.nano.2016.11.01210.1016/j.nano.2016.11.012 ↗
32. 10.1021/acsami.9b0582710.1021/acsami.9b05827 ↗
33. 10.1016/j.biomaterials.2017.07.03610.1016/j.biomaterials.2017.07.036 ↗
34. 10.1021/acsapm.9b0061610.1021/acsapm.9b00616 ↗
35. 10.1089/ars.2013.573310.1089/ars.2013.5733 ↗
36. 10.1016/j.ajps.2018.07.00510.1016/j.ajps.2018.07.005 ↗
37. 10.1021/acsnano.5b0387610.1021/acsnano.5b03876 ↗
38. 10.1002/adma.20180300110.1002/adma.201803001 ↗
39. 10.1016/j.jcis.2017.02.03310.1016/j.jcis.2017.02.033 ↗
40. 10.1016/j.colsurfb.2011.09.04310.1016/j.colsurfb.2011.09.043 ↗
41. 10.1016/j.jconrel.2018.10.00710.1016/j.jconrel.2018.10.007 ↗
42. 10.1016/j.actbio.2017.06.03710.1016/j.actbio.2017.06.037 ↗
43. 10.1002/smll.20190332310.1002/smll.201903323 ↗
44. 10.1021/mp300589710.1021/mp3005897 ↗
45. 10.1134/s000629791503004910.1134/s0006297915030049 ↗
46. 10.1021/acsami.7b0705610.1021/acsami.7b07056 ↗
47. 10.1016/j.nantod.2017.12.00710.1016/j.nantod.2017.12.007 ↗
48. 10.1002/smll.20170181510.1002/smll.201701815 ↗
49. 10.1016/j.biomaterials.2013.03.06510.1016/j.biomaterials.2013.03.065 ↗
50. 10.1016/j.jconrel.2014.09.02010.1016/j.jconrel.2014.09.020 ↗
51. 10.1021/acsami.9b0890110.1021/acsami.9b08901 ↗
52. 10.1016/j.jconrel.2015.03.01810.1016/j.jconrel.2015.03.018 ↗
53. 10.1002/adma.20190151310.1002/adma.201901513 ↗